DSGN Stock — Design Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$15.03

Market cap

$971.89M

Price action

19 metrics

Price change (1W)

-0.4%

Price change (30D)

+17.7%

Price change (3M)

+48.8%

Price change (6M)

+49.8%

Price change (YTD)

+65.6%

Price change (1Y)

+171.0%

Trailing year

Price change (5Y)

-8.8%

52-week high

$15.94

52-week low

$5.53

Change from 52-week high

-2.6%

Change from 52-week low

+180.8%

Annualized volatility

78.0%

Beta

1.2

RSI (14D)

62.1

Price vs SMA 50

+10.8%

Price vs SMA 200

+34.3%

Avg volume (3M)

691,616

Relative volume

1.5

Average dollar volume

$9.39M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

62.58M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

4.8

reciprocal yield 20.8%

FCF yield

-5.7%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-7.3%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-04-28

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$79.36M

Net income (TTM)

−$70.80M

Trailing 12 months

Diluted EPS (TTM)

$-1.18

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-0.71

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+9.9%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-35.1%

Return on assets

-32.9%

Debt / equity

—

Current ratio

18.9

EBITDA (TTM)

—

Free cash flow (TTM)

−$55.14M

Quick ratio

18.9

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$207.40M

Latest balance sheet

Cash & equivalents

$12.91M

Total assets

$215.13M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$55.08M

Capital expenditures (TTM)

$55,000

R&D (TTM)

$58.78M

SG&A (TTM)

—

Stock compensation (TTM)

$14.82M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

137

13F filer change QoQ

+12

Institutional ownership

71.7%

Short interest

3 metrics

Short interest

9.5%

Latest settlement · 15.2 days to cover

Days to cover

15.2d

Short-squeeze score

73 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

DSGN · Design Therapeutics, Inc.

DSGN metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search